PAC-1是一种具有口服活性的小分子procaspase-3激活剂，可诱导癌细胞凋亡，EC50为2.08μM。
Cas No.:315183-21-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PAC-1 is an orally active small-molecule procaspase-3 activator that induces cancer cell apoptosis with an EC50 of 2.08μM. PAC-1 can be used in the research of malignant tumors and hematologic cancers[1-4].
In vitro, PAC-1 (10–50μM) was added to HeLa cervical cancer cells for 15min, significantly reduced the intracellular free Zn²⁺ concentration, triggered endoplasmic reticulum (ER) Ca²⁺ release, and increased the cytoplasmic Ca²⁺ concentration. PAC-1 (25μM) was applied to U-937 lymphoma cells or HL-60 leukemia cells for 6h, significantly upregulating the expression of genes such as DDIT4, JUN, ATF3, and TNF, thereby inducing apoptosis. PAC-1 (100μM) was administered to U-937 lymphoma cells for 1–3h or to HeLa cells for 15–60min, which significantly induced ER stress and mitochondrial morphological speckling, downregulated TNF expression, and triggered cell death[5]. PAC-1 (1–30μM) was incubated with UMR106 osteosarcoma-like cells for 24h, significantly upregulating Fgf23 gene expression while reducing cell proliferation and viability[6].
In vivo, PAC-1 (0.15, 1.5, or 15nmol/site; single) was subcutaneously injected into the periorbital region of C57BL/6J mice. PAC-1 significantly induced dose-dependent and sustained periorbital mechanical allodynia[7]. PAC-1 (50mg/kg; once daily) was intraperitoneally injected into SCID or Balb/c nude mice bearing human breast cancer (MDA-MB-435), liver cancer (Hep3B), or gallbladder cancer (GBC-SD) xenografts for 30 days. PAC-1 significantly inhibited the in vivo growth of these tumors, which highly expressed procaspase-3[8].
References:
[1] Seervi M, Sobhan PK, Joseph J, et al. ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1). Cell Death Dis. 2013 Dec 19;4(12):e968.
[2] Putt KS, Chen GW, Pearson JM, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50.
[3] Rees TA, Labastida-Ramírez A, Rubio-Beltrán E. Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research. Trends Pharmacol Sci. 2023 Oct;44(10):651-663.
[4] Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64.
[5] West DC, Qin Y, Peterson QP, et al. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Mol Pharm. 2012 May 7;9(5):1425-34.
[6] Münz S, Feger M, Edemir B, et al. Up-Regulation of Fibroblast Growth Factor 23 Gene Expression in UMR106 Osteoblast-like Cells with Reduced Viability. Cells. 2021 Dec 23;11(1):40.
[7] De Logu F, Landini L, Janal MN, et al. Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019 Feb 14;20(1):18.
[8] Wang F, Wang L, Zhao Y, et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Mol Oncol. 2014 Dec;8(8):1640-52.
PAC-1是一种具有口服活性的小分子procaspase-3激活剂，可诱导癌细胞凋亡，EC50为2.08μM。PAC-1可用于恶性肿瘤和血液系统癌症的相关研究[1-4]。
在体外，PAC-1（10–50μM）处理HeLa宫颈癌细胞15min，显著降低细胞内游离Zn²⁺浓度，触发内质网Ca²⁺释放及细胞质Ca²⁺浓度升高；PAC-1（25μM）处理U-937淋巴瘤细胞或HL-60白血病细胞6h，显著上调DDIT4、JUN、ATF3及TNF等基因的表达，诱导细胞凋亡；PAC-1（100μM）处理U-937淋巴瘤细胞1-3h或HeLa细胞15-60min，显著诱导内质网（ER）应激及线粒体形态斑点化，下调TNF等基因表达并引发细胞死亡[5]。PAC-1（1–30μM）处理UMR106骨肉瘤样细胞24h，显著上调Fgf23基因的表达，同时降低细胞增殖和活力[6]。
在体内，PAC-1（0.15、1.5或15nmol/site；单次）皮下注射于C57BL/6J小鼠的眼眶周区域。PAC-1显著诱导了剂量依赖性和持续性的眶周机械性异位痛[7]。PAC-1（50mg/kg；每日一次）腹腔注射于携带人类乳腺癌（MDA-MB-435）、肝癌（Hep3B）或胆囊癌（GBC-SD）异种移植物的SCID或Balb/c裸鼠30天。PAC-1显著抑制了这些高表达procaspase-3的肿瘤在体内的生长[8]。
| Cell experiment [1]: | |
Cell lines | UMR106 cells (rat osteoblast-like cell line) |
Preparation Method | UMR106 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 25mM glucose and 1mM pyruvate, supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, and 100μg/mL streptomycin at 37°C, 5% CO₂. After seeding into 6-well plates for 24h, UMR106 cells were treated with PAC-1 (1-10μM) for 24 hours. |
Reaction Conditions | 1-10μM; 24h |
Applications | PAC-1 significantly up-regulated Fgf23 gene expression in UMR106 cells. PAC-1 also reduced cell proliferation and viability in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | 7- to 8-week old male SCID mice and Balb/c nude mice bearing human tumor xenografts (MDA-MB-435 breast cancer, Hep3B liver cancer, GBC-SD gallbladder cancer, or MCF-7 breast cancer). |
Preparation Method | When the average subcutaneous tumor volume reached approximately 100mm³, mice were randomly divided into treatment and control groups (eight mice per group). PAC-1 was administered via intraperitoneal injection once daily for a period of two to four weeks. Mice were subsequently sacrificed, and tumors were excised and stored at -80°C for further analysis. |
Dosage form | 50mg/kg; i.p.; once daily for 30 days |
Applications | PAC-1 significantly inhibited the in vivo growth of MDA-MB-435, Hep3B, and GBC-SD xenograft tumors which overexpress procaspase-3. Conversely, PAC-1 had no effect on the growth of MCF-7 xenograft tumors, which do not express procaspase-3. The administration of PAC-1 did not induce substantial weight loss but was associated with signs of neurotoxicity (ataxia) at high doses. |
References: | |
| Cas No. | 315183-21-2 | SDF | |
| 别名 | Procaspase activating compound 1 | ||
| 化学名 | 2-(4-benzylpiperazin-1-yl)-N'-[(Z)-(6-oxo-5-prop-2-enylcyclohexa-2,4-dien-1-ylidene)methyl]acetohydrazide | ||
| Canonical SMILES | C=CCC1=CC=CC(=CNNC(=O)CN2CCN(CC2)CC3=CC=CC=C3)C1=O | ||
| 分子式 | C23H28N4O2 | 分子量 | 392.49 |
| 溶解度 | ≥ 13.4mg/mL in DMSO, ≥ 6.87 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5478 mL | 12.7392 mL | 25.4784 mL |
| 5 mM | 509.6 μL | 2.5478 mL | 5.0957 mL |
| 10 mM | 254.8 μL | 1.2739 mL | 2.5478 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet